Patients with HF documented were less likely to be treated with metformin (HF documented vs. no: 45.6% vs. 50.4%, standardized difference 9.7%), thiazolidinediones (5.1% vs. 7.7%, standardized difference 10.3%), GLP-1 receptor agonists (6.2% vs. 10.3%, standardized difference 14.8%), and SGLT2 inhibitors (4.4$ vs. 7.1%, standardized difference 11.8%). This evidence concerns the gene SLC5A2 and hydrops fetalis.